share_log

8-K: Current report

8-K: Current report

8-K:重大事件
美股SEC公告 ·  07/05 16:17
Moomoo AI 已提取核心訊息
On July 3, 2024, SeaStar Medical Holding Corporation notified The Nasdaq Stock Market LLC of a possible violation of Nasdaq Listing Rule 5635(d)(2) concerning the issuance of shares without shareholder approval. The issue arose from the conversion of convertible notes and exercise of warrants issued to an institutional investor. These financial instruments were part of a Securities Purchase Agreement from March 15, 2023, which was approved by shareholders at the Annual Meeting on June 28, 2023. Amendments to the agreement on August 7, 2023, and December 11, 2023, involved additional convertible notes and warrants, with adjustments to conversion and exercise prices. SeaStar Medical has requested Nasdaq to review the transactions for compliance and has committed to adhering to Nasdaq's shareholder approval requirements for future securities issuances.
On July 3, 2024, SeaStar Medical Holding Corporation notified The Nasdaq Stock Market LLC of a possible violation of Nasdaq Listing Rule 5635(d)(2) concerning the issuance of shares without shareholder approval. The issue arose from the conversion of convertible notes and exercise of warrants issued to an institutional investor. These financial instruments were part of a Securities Purchase Agreement from March 15, 2023, which was approved by shareholders at the Annual Meeting on June 28, 2023. Amendments to the agreement on August 7, 2023, and December 11, 2023, involved additional convertible notes and warrants, with adjustments to conversion and exercise prices. SeaStar Medical has requested Nasdaq to review the transactions for compliance and has committed to adhering to Nasdaq's shareholder approval requirements for future securities issuances.
2024年7月3日,SeaStar醫療控股公司通知納斯達克證券交易所可能存在違反納斯達克上市規則5635(d)(2)的問題,即未經股東批准發行股份。該問題源於向機構投資者發行可轉換票據和認股證,這些金融工具是2023年3月15日證券購買協議的一部分,協議已於2023年6月28日的年度股東大會獲得批准。2023年8月7日和12月11日的協議修訂涉及額外的可轉換票據和認股證,並調整了轉換和行使價格。SeaStar醫療已要求納斯達克審查交易以確保合規,並承諾遵守納斯達克對未來證券發行的股東批准要求。
2024年7月3日,SeaStar醫療控股公司通知納斯達克證券交易所可能存在違反納斯達克上市規則5635(d)(2)的問題,即未經股東批准發行股份。該問題源於向機構投資者發行可轉換票據和認股證,這些金融工具是2023年3月15日證券購買協議的一部分,協議已於2023年6月28日的年度股東大會獲得批准。2023年8月7日和12月11日的協議修訂涉及額外的可轉換票據和認股證,並調整了轉換和行使價格。SeaStar醫療已要求納斯達克審查交易以確保合規,並承諾遵守納斯達克對未來證券發行的股東批准要求。
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息